mdlinx mdlinx
Latest (90) Full Text Articles (1570) Focus on Barrett's Esophagus Article Summary

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial
Gut,  Clinical Article

Hueber W et al. – Blockade of interleukin (IL)–17A was ineffective and higher rates of adverse events were noted compared with placebo.

Methods
  • In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥220 to ≤450) were assigned in a 2:1 ratio to 2×10 mg/kg intravenous secukinumab or placebo.
  • The primary end point, addressed by Bayesian statistics augmented with historical placebo information, was the probability that secukinumab reduces the CDAI by ≥50 points more than placebo at week 6.
  • Ancillary analyses explored associations of 35 candidate genetic polymorphisms and faecal calprotectin response.

Results
  • 59 patients (39 secukinumab, 20 placebo, mean baseline CDAI 307 and 301, respectively) were recruited.
  • 18/59 (31%) patients discontinued prematurely (12/39 (31%) secukinumab, 6/20 (30%) placebo), 10/59 (17%) due to insufficient therapeutic effect (8/39 (21%) secukinumab, 2/20 (10%) placebo).
  • Fourteen serious adverse events occurred in 10 patients (seven secukinumab, three placebo); 20 infections, including four local fungal infections, were seen on secukinumab versus none on placebo.
  • Primary end point analysis estimated <0.1% probability (ΔCDAI (SD)=33.9 (19.7), 95% credible interval -4.9 to 72.9) that secukinumab reduces CDAI by ≥50 points more than placebo.
  • Secondary area under the curve analysis (weeks 4-10) showed a significant difference (mean ΔCDAI=49; 95% CI (2 to 96), p=0.043) in favour of placebo.
  • Post hoc subgroup analysis showed that unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers (CRP≥10 mg/l and/or faecal calprotectin≥200 ng/ml; mean ΔCDAI=62; 95% CI (-1 to 125), p=0.054 in favour of placebo).
  • Absence of the minor allele of tumour necrosis factor-like ligand 1A was strongly associated with lack of response measured by baseline-adjusted changes in calprotectin at week 6 (p=0.00035 Bonferroni-corrected).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2013

1 Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease Alimentary Pharmacology and Therapeutics, February 28, 2014    Clinical Article

2 Fungal microbiota and digestive diseases Alimentary Pharmacology and Therapeutics, March 5, 2014    Review Article

3 Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy. A case-control study Journal of Gastroenterology and Hepatology, March 27, 2014    Clinical Article

4 Once versus three times daily dosing of oral budesonide for active Crohns disease: A double-blind, double-dummy, randomised trial Journal of Crohn's and Colitis, February 21, 2014    Clinical Article

5 Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: An open-label multicentre study Alimentary Pharmacology and Therapeutics, March 25, 2014    Clinical Article

6 Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease Helicobacter, March 21, 2014    Clinical Article

7 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

8 Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial Complementary Therapies in Medicine, March 4, 2014    Clinical Article

9 Role of vitamin D derivatives in intestinal tissue of patients with inflammatory bowel diseases Journal of Crohn's and Colitis, March 17, 2014    Clinical Article

10 Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation Clinical Gastroenterology and Hepatology , January 17, 2014    Clinical Article

11 Calcium intake and colorectal cancer risk: Dose-response meta-analysis of prospective observational studies International Journal of Cancer, March 14, 2014    Evidence Based Medicine    Clinical Article

12 Disease course and surgery rates in inflammatory bowel disease: A population-based, 7-year follow-up study in the era of immunomodulating therapy The American Journal of Gastroenterology, March 19, 2014    Clinical Article

13 A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease Journal of Crohn's and Colitis, March 5, 2014    Clinical Article

14 The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis Alimentary Pharmacology and Therapeutics, March 12, 2014    Clinical Article

15 Use of proton pump inhibitors and subsequent risk of celiac disease Digestive and Liver Diseases, September 20, 2013    Clinical Article

16 Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy Gastroenterology, February 28, 2014    Clinical Article

17 Iron treatment and inflammatory bowel disease Journal of Crohn's and Colitis, February 11, 2014    Clinical Article

18 Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease Clinical Gastroenterology and Hepatology , March 4, 2014    Clinical Article

19 Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C Gastroenterology, February 28, 2014    Clinical Article

20 Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: Changes following treatment with immunomodulators and/or anti-TNF antibodies Journal of Crohn's and Colitis, March 24, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close